Henry Couture, 20-Year Medical Device Quality Professional, Joins CytoVeris as Director of Quality
Share Article
Medical technology company driven by the mission to elevate the quality of cancer care through AI-driven optical-guided surgical tools appoints Director of Quality to lead quality system management initiatives during critical time of growth FARMINGTON, Conn. (PRWEB) May 04, 2021
CytoVeris Inc., an emerging company formed with the vision of harnessing advanced technology and real-time AI solutions to enhance the quality of surgical oncology and improve patient care, today announced that Henry Couture has joined the company as Director of Quality. Mr. Couture has an extensive background with over 20 years of experience leading quality and safety initiatives. As Director of Quality, Mr. Couture will further develop CytoVeris’ quality system and ensure compliance as the company readies itself for FDA app
Future Market Insights: Radiotherapy Devices Market to Receive Tailwinds, with Surge in Popularity among Oncologists: Future market Insights
Lack of trained professionals is anticipated to hinder growth of the radiotherapy devices market.
COVID-19 Impact on the Market
The COVID-19 outbreak has impact all the fields of healthcare provision including radiotherapy devices market. There has been a drop in critical referrals from general practitioners to cancer facilities for individuals and likewise a decline in chemotherapy appointments from cancer patients. However, the market is anticipated to recover prompted by pent-up demand for cancer diagnosis and treatment.
Competitive Landscape
Key market players identified in the global radiotherapy devices market are Elekta AB, Varian Medical Systems, Accuray, Inc., Inc., C.R. Bard, IBA Ion Beam Applications SA, Siemens AG, Koninklijke Philips N.V., Eckert & Ziegler Bebig, GE Healthcare, IsoRay, Inc., Vision RT Ltd., Theragenics Corp, Ra